<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897676</url>
  </required_header>
  <id_info>
    <org_study_id>2008-10-6255</org_study_id>
    <secondary_id>R01FD004905</secondary_id>
    <nct_id>NCT00897676</nct_id>
  </id_info>
  <brief_title>Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity</brief_title>
  <official_title>Role of GLP-1 in Congenital Hyperinsulinism:Effect of Exendin-(9-39) on Fasting Adaptation and Protein Sensitivity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diva De Leon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of exendin-(9-39) on fasting blood
      glucose and protein induced hypoglycemia on subjects with Congenital Hyperinsulinism. Funding
      Source - FDA Office of Orphan Products Development (OODP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo controlled study with randomized crossover design to evaluate the effect of
      the glucagon-like peptide-1 (GLP-1) receptor antagonist, exendin-(9-39), on fasting blood
      glucose levels, protein-induced hypoglycemia, and fasting tolerance of subjects with
      congenital hyperinsulinism due to mutations in the ATP- sensitive potassium channel (KATP)
      channel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>In a random crossover design, subjects were assigned to either intervention (6 hour infusion of exendin( 9-39) at a dose range of 100-500pmol/kg/min) or vehicle (6hr infusion of 0.9%NaCl)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve (AUC) Plasma Glucose</measure>
    <time_frame>Time 0 min - time 360 min</time_frame>
    <description>Area under the curve plasma glucose from the initiation of infusion of vehicle or exendin-(9-39) to end of the infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Plasma Insulin</measure>
    <time_frame>time 0 min to time 360 min</time_frame>
    <description>Area under the curve plasma insulin from the initiation of infusion of vehicle or exendin-(9-39) to end of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Plasma C-peptide</measure>
    <time_frame>time 0 min to time 360 min</time_frame>
    <description>Area under the curve plasma C-peptide from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) Plasma Glucagon</measure>
    <time_frame>time 0 min to time 360 min</time_frame>
    <description>Area under the curve plasma glucagon from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve ( AUC) Plasma Total GLP-1 (Glucagon-like Peptide-1)</measure>
    <time_frame>time 0 to time 360 min</time_frame>
    <description>Area under the curve plasma total GLP-1 (glucagon-like peptide-1) from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve ( AUC) Plasma Active GLP-1 (Glucagon-like Peptide-1)</measure>
    <time_frame>time 0 min to time 360 min</time_frame>
    <description>Area under the curve plasma active GLP-1 (glucagon-like peptide-1) from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Congenital Hyperinsulinism</condition>
  <arm_group>
    <arm_group_label>Vehicle first, then Exendin-(9-39)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exendin-(9-39) first then Vehicle.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). . At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, GLP-1, and glucagon will be measured every 30 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exendin-(9-39)</intervention_name>
    <description>100-500pmol/kg/min</description>
    <arm_group_label>Vehicle first, then Exendin-(9-39)</arm_group_label>
    <arm_group_label>Exendin-(9-39) first then Vehicle.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo (0.9% NaCl)</description>
    <arm_group_label>Vehicle first, then Exendin-(9-39)</arm_group_label>
    <arm_group_label>Exendin-(9-39) first then Vehicle.</arm_group_label>
    <other_name>(0.9% NaCl)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of hyperinsulinism

          -  Mutation analysis results demonstrating KATP channel defect

          -  Age 6 months to 18 years with

          -  Persistent hypoglycemia

        Exclusion Criteria:

          -  Current therapy with medications that may affect glucose metabolism such as
             octreotide, diazoxide, high dose glucocorticoids, adrenergic agents, etc. Subjects
             will be eligible to participate if the last dose of octreotide is given 48 hrs before
             study day 1 and the last dose of diazoxide is given 72 hours before study day 1

          -  Evidence of a medical condition that might alter results or compromised the
             elimination of the peptide, including active infection, kidney failure, severe liver
             dysfunction, severe respiratory or cardiac failure

          -  Pregnancy

          -  Subjects with milk protein allergy will be excluded for participating in studies
             involving protein tolerance test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diva D DeLeon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2009</study_first_submitted>
  <study_first_submitted_qc>May 8, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <results_first_submitted>November 9, 2017</results_first_submitted>
  <results_first_submitted_qc>December 19, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">January 18, 2018</results_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital of Philadelphia</investigator_affiliation>
    <investigator_full_name>Diva De Leon</investigator_full_name>
    <investigator_title>M.D. Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Hyperinsulinism</keyword>
  <keyword>Hypoglycemia</keyword>
  <keyword>KATP channel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperinsulinism</mesh_term>
    <mesh_term>Congenital Hyperinsulinism</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects age 6months to 18 years with congenital hyperinsulinism due to mutations in the Katp channel( KatpHI) were recruited from the Hyperinsulinism Center at The Children's Hospital of Philadelphia</recruitment_details>
      <pre_assignment_details>17 subject were enrolled (consented). One(1) withdrawn</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vehicle First Then Exendin-(9-39)</title>
          <description>An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. The following day, at time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, glucagon-like peptide-(GLP-1) , and glucagon will be measured every 30 minutes.
Vehicle: (0.9% NaCl)</description>
        </group>
        <group group_id="P2">
          <title>Exendin-(9-39) First Then Vehicle</title>
          <description>An infusion of vehicle (0.9%NaCl) will run for 60 minutes(time -60 to 0) before starting the study infusion of vehicle or exendin-(9-39). At time 0, exendin-(9-39) at a dose ranging from 100-500pmol/kg/min will be started and continue for 6 hours. The following day, at time 0, vehicle (0.9%NaCl) will be started and will continue for 6 hours. During both infusions, blood glucose, insulin, c-peptide, glucagon-like peptide-(GLP-1) , and glucagon will be measured every 30 minutes.
Exendin-(9-39): 100-500pmol/kg/min</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Intervention 1(6 Hours)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Intervention 2(6 Hours)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subject Population</title>
          <description>9 subjects were randomized to the vehicle first arm and the next day they were switched to exendin- (9-39). 7 subjects were randomized to the exendin-(9-39) first arm and the next day they were switched to vehicle. All subjects enrolled and treated in the protocol served as their own control. Because of this and the small sample size, baseline characteristic data is presented together.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve (AUC) Plasma Glucose</title>
        <description>Area under the curve plasma glucose from the initiation of infusion of vehicle or exendin-(9-39) to end of the infusion</description>
        <time_frame>Time 0 min - time 360 min</time_frame>
        <population>A total of 16 subjects were included in the analysis. 1 subject was withdrawn.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Subjects received an infusion of vehicle( 0.9%NaCl) intravenously from time 0 min to 360 min
Vehicle: (0.9% NaCl)</description>
          </group>
          <group group_id="O2">
            <title>Exendin-(9-39)</title>
            <description>Subjects received an infusion of exendin-(9-39) intravenously at a dose ranging from 100-500pmol/kg/min from time 0 min to 360 min
Exendin-(9-39)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Plasma Glucose</title>
          <description>Area under the curve plasma glucose from the initiation of infusion of vehicle or exendin-(9-39) to end of the infusion</description>
          <population>A total of 16 subjects were included in the analysis. 1 subject was withdrawn.</population>
          <units>mg*min/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26994.7" spread="4219.8"/>
                    <measurement group_id="O2" value="32122.2" spread="6650.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Plasma Insulin</title>
        <description>Area under the curve plasma insulin from the initiation of infusion of vehicle or exendin-(9-39) to end of the infusion</description>
        <time_frame>time 0 min to time 360 min</time_frame>
        <population>data from only 15 subjects because the values were below the level of detection for one subject.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Subjects received an infusion of vehicle( 0.9%NaCl) intravenously from time 0 to time 360 min
Vehicle: (0.9% NaCl)</description>
          </group>
          <group group_id="O2">
            <title>Exendin-(9-39)</title>
            <description>Subjects received an infusion of exendin-(9-39) intravenously from time 0 to time 360 min at a dose of 100-500 pmol/kg/min
Exendin-(9-39)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Plasma Insulin</title>
          <description>Area under the curve plasma insulin from the initiation of infusion of vehicle or exendin-(9-39) to end of the infusion</description>
          <population>data from only 15 subjects because the values were below the level of detection for one subject.</population>
          <units>uIU*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1649.9" spread="1089"/>
                    <measurement group_id="O2" value="1334.1" spread="535.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Plasma C-peptide</title>
        <description>Area under the curve plasma C-peptide from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
        <time_frame>time 0 min to time 360 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Subjects received an infusion of vehicle( 0.9%NaCl) intravenously from time 0 min to time 360 min
Vehicle: (0.9% NaCl)</description>
          </group>
          <group group_id="O2">
            <title>Exendin-(9-39)</title>
            <description>Subjects received an infusion of exendin-(9-39) intravenously at a dose ranging from 100-500pmol/kg/min from time 0 min to time 360 min
Exendin-(9-39)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Plasma C-peptide</title>
          <description>Area under the curve plasma C-peptide from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
          <units>ng*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.4" spread="155.8"/>
                    <measurement group_id="O2" value="236.6" spread="112.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve (AUC) Plasma Glucagon</title>
        <description>Area under the curve plasma glucagon from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
        <time_frame>time 0 min to time 360 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Subjects receive an infusion of vehicle( 0.9%NaCl) intravenously from time 0 to time 360 min
Vehicle: (0.9% NaCl)</description>
          </group>
          <group group_id="O2">
            <title>Exendin-(9-39)</title>
            <description>Subjects received an infusion of exendin-(9-39) intravenously at a dose ranging from 100-500pmol/kg/min from time 0 to time 360 min
Exendin-(9-39)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve (AUC) Plasma Glucagon</title>
          <description>Area under the curve plasma glucagon from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
          <units>pg*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22806.8" spread="10210.3"/>
                    <measurement group_id="O2" value="23409.4" spread="11396.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve ( AUC) Plasma Total GLP-1 (Glucagon-like Peptide-1)</title>
        <description>Area under the curve plasma total GLP-1 (glucagon-like peptide-1) from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
        <time_frame>time 0 to time 360 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Subjects received an infusion of vehicle( 0.9%NaCl) intravenously from time 0 to time 360 min
Vehicle: (0.9% NaCl)</description>
          </group>
          <group group_id="O2">
            <title>Exendin-(9-39)</title>
            <description>Subjects received an infusion of exendin-(9-39) intravenously at a dose ranging from 100-500pmol/kg/min from time 0 to time 360 min
Exendin-(9-39)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve ( AUC) Plasma Total GLP-1 (Glucagon-like Peptide-1)</title>
          <description>Area under the curve plasma total GLP-1 (glucagon-like peptide-1) from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
          <units>pmol*min/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4899.3" spread="2598.8"/>
                    <measurement group_id="O2" value="5698.8" spread="3484.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve ( AUC) Plasma Active GLP-1 (Glucagon-like Peptide-1)</title>
        <description>Area under the curve plasma active GLP-1 (glucagon-like peptide-1) from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
        <time_frame>time 0 min to time 360 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Subjects received an infusion of vehicle( 0.9%NaCl) intravenously from time 0 min to time 360 min
Vehicle</description>
          </group>
          <group group_id="O2">
            <title>Exendin-(9-39)</title>
            <description>Subjects received an infusion of exendin-(9-39) intravenously at a dose ranging from 100-500pmol/kg/min from time 0 min to time 360 min
Exendin-(9-39)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve ( AUC) Plasma Active GLP-1 (Glucagon-like Peptide-1)</title>
          <description>Area under the curve plasma active GLP-1 (glucagon-like peptide-1) from the beginning of the infusion of vehicle or exendin-(9-39) to the end of the infusion</description>
          <units>pmol*min/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1373.7" spread="1044"/>
                    <measurement group_id="O2" value="1432.9" spread="1114.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline to 24 hours after the end of study of infusion.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>Subjects received an infusion of vehicle (0.9% NaCl) intravenously from time 0 min to time 360 min
Vehicle: (0.9% NaCl)</description>
        </group>
        <group group_id="E2">
          <title>Exendin-(9-39)</title>
          <description>Subjects received an infusion of exendin-(9-39) intravenously at a dose ranging from 100-500pmol/kg/min from time 0 min to time 360 min
Exendin-(9-39)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="16"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>For safety reasons, blood glucose levels were maintained above a safety threshold (55-60mg/dL) during the study by infusing dextrose intravenously which may limit the magnitude of the effect that we will be able to detect.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Diva DeLeon, MD</name_or_title>
      <organization>The Children's Hospital of Philadelphia</organization>
      <phone>267-426-5529</phone>
      <email>deleon@email.chop.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

